10-Q · May 7, 2026
Processa Pharmaceuticals, in its Q1 2026 10-Q filing, reported a continuing trend of net losses, with a net loss of $3.38 million compared to $2.83 million in Q1 2025. The company remains in the clinical trial phase…
Earnings analysis · 10-Q
PCSA earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q text does not disclose revenue, margins, EPS, balance-sheet balances, cash flow, capex or segment results, so quarter-over-quarter and year-over-year operating trends cannot be assessed. Post-quarter…
Read full summary
The extracted 10-Q text does not disclose revenue, margins, EPS, balance-sheet balances, cash flow, capex or segment results, so quarter-over-quarter and year-over-year operating trends cannot be assessed. Post-quarter developments materially increase execution and financing risk: the PCS6422 program was returned to Elion following a $650,000 settlement payment, while the company is concentrating resources on VT-7208. The Vidya Acquisition also introduces integration costs and potential dilution of up to 307,063,330 shares, or approximately 99.0% of common shares on an as-converted basis.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Vidya integration underway
The Vidya Acquisition was completed after June 30, 2026, and management expects integration of Vidya's financial processes, systems and personnel to continue through the remainder of 2026.
-
PCS6422 litigation resolved
The PCS6422 litigation was settled on July 23, 2026; Processa paid Elion $650,000, returned the PCS6422 program, and the litigation was dismissed with prejudice on August 7, 2026.
-
Pipeline refocused on VT-7208
Processa stated that it is focusing the majority of its resources on VT-7208 across food allergy, CSU and RMS, while continuing development of PCS499, PCS12852 and PCS11T.
-
Controls assessed as effective
Management concluded that disclosure controls were effective as of June 30, 2026, and reported no material changes in internal control over financial reporting during the quarter.
What to watch
-
High dependence on VT-7208
The company said it is focusing the vast majority of its resources on VT-7208 and has no products approved for commercial sale. Failure or delay in VT-7208 development could therefore have a disproportionate impact on the business.
-
Severe potential equity dilution
Up to 307,063,330 common shares may be issued upon conversion of Series A Preferred Stock, representing approximately 99.0% of issued and outstanding common shares as of August 7, 2026 on an as-converted basis, creating substantial dilution and resale risk.
-
Preferred-stock cash settlement risk
The company must recommend approval of the Series A Preferred Stock conversion and related stockholder matters; if conversion cannot be delivered, holders may require cash settlement after 6 months from the initial issuance date, which could materially harm operations and financial condition.
Management's outlook
No quantitative revenue or EPS outlook was provided in the extracted 10-Q text. Outlook deferred/not provided.
Earlier filings 4
10-K · April 30, 2026
Processa Pharmaceuticals continues to focus on clinical development with a reported diluted EPS of -1.3 in Q4 2026, aligning with consensus estimates, while maintaining a stable operational status due to ongoing trials.…
10-K · March 18, 2026
Processa is a clinical-stage biopharmaceutical company focused on 'Next Generation Cancer' (NGC) therapies that modify metabolism/distribution of established oncology drugs. The company has enrolled and dosed the 20…
10-Q · May 8, 2025
Processa Pharmaceuticals reported a net loss of $2,834,405 for the quarter ended March 31, 2025 versus a loss of $2,726,381 in the prior-year quarter, while GAAP loss per share improved to $(0.30) from $(1.11) due to a…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.